Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
Top Cited Papers
- 24 January 2020
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 31 (3), 377-386
- https://doi.org/10.1016/j.annonc.2019.11.006
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- GlaxoSmithKline Australia
- Novartis
- Fondation ARC pour la Recherche sur le Cancer
- Roche
- Servier
- Association pour la Recherche sur le Cancer
- Pfizer
- Sanofi Pasteur
- Amgen
- Eli Lilly and Company
- Breast Cancer Research Foundation (266559)
- Takeda Pharmaceutical Company
This publication has 30 references indexed in Scilit:
- PIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroupsBreast Cancer Research, 2012
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in CancerNucleic Acids Research, 2010
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- PIK3CA Mutation Associates with Improved Outcome in Breast CancerClinical Cancer Research, 2009
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast CancerCancer Research, 2008
- Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese WomenClinical Cancer Research, 2007
- Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial CellsCancer Research, 2005
- PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast CarcinomaCancer Research, 2005
- The Phosphoinositide 3-Kinase PathwayScience, 2002